EMA Validates Marketing Authorization Application for Henlius’ HANSIZHUANG (Serplulimab)

HANSIZHUANG (serplulimab) is the first anti-PD-1 mAb for the first-line treatment of small cell lung cancer (SCLC) The EC and the FDA previously granted Orphan Drug Designations (ODDs) for HANSIZHUANG in SCLC HANSIZHUANG is approved in China for microsatellite instability-high (MSI-H)…